An animal study by the National Institute of Environmental Health Sciences

Brain disease one step closer to slowing the onset and progression of Alzheimer’s disease have progression of Alzheimer’s disease by targeting the blood-brain barrier may be delayed . An animal study by the National Institute of Environmental Health Sciences , part of the National Institutes of Health shows support that targeted the blood-brain barrier, researchers were able to prevent the accumulation of a protein with the progression of the associated are slowly disease. The blood – brain barrier into the brain separates from the circulating blood, and it protects the brain by removing toxic metabolites and proteins in the brain and preventing entry of toxic chemicals is formed from the blood.

This study is the experimental basis for new policies that are used to Alzheimer’s patients can be treated, said David S. Director of the Laboratory of Toxicology and Pharmacology at NIEHS and an author on the paper, which in the May issue of Molecular Pharmacology appears.

‘As is the first study data show superiority of MoxDuo IR a view to analgesic effect, used also important findings were regarding superior a total relief of pain, reducing reliance on supplementary analgesia and powerful tolerability, ‘said Dr. John Holaday, Managing Director and Chief Executive Officer of, QRxPharma. ‘These results are are consistent with earlier comparable data and enhance both and commercial potential of and commercial potential of our leading edge MoxDuo infrared Dual – opioid products candidate. ‘.